TWP-102

TWP-102 is an investigational drug developed for the treatment of advanced malignancies, including solid tumors and non-Hodgkin lymphoma. It is being evaluated as an intravenous injection in a multicenter, open-label, dose-escalation and dose-expansion Phase 1 clinical trial. The primary objectives are to assess safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and preliminary antitumor efficacy. Preclinical studies suggest that TWP-102 may have superior anti-tumor efficacy and safety compared to ipilimumab. The precise mechanism of action has not been disclosed publicly; however, it is classified as a coagulation factor modality[1][2][10]. The drug is under development by Therawisdom Biopharma Co., Ltd., with Shandong Pharmaceutical also listed as a developer or manufacturer[1][2][3].